Clinical Trials
196 trialsRAINFOL-01
Genmab
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
AstraZeneca
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
AMBITION
Japanese Foundation for Cancer Research
MEDIOLA
AstraZeneca
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
Morpheus-panBC
Hoffmann-La Roche
PRELUDE
Japanese Foundation for Cancer Research
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
MORPHEUS HR+BC
Hoffmann-La Roche
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
University of California, Irvine
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
National Cancer Institute (NCI)
SAFIR02_Breast
UNICANCER
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
Fudan University
ECLIPSE
Queen Mary University of London
ATRACTIB
MedSIR
PTST_PALBEVA
Lebanese University
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
University of California, Irvine
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
MARIO-3
Infinity Pharmaceuticals, Inc.
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Eastern Cooperative Oncology Group
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Spanish Breast Cancer Research Group
A Phase â… b/â…¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Jiangsu HengRui Medicine Co., Ltd.
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Rutgers, The State University of New Jersey
COMET
UNICANCER
RIBBIT
iOMEDICO AG
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Hoffmann-La Roche
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
University of Alabama at Birmingham
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
BOOSTER
Japan Breast Cancer Research Group
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP Foundation Inc
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ABCDE
Dana-Farber Cancer Institute
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
SCRI Development Innovations, LLC
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Novartis